176 related articles for article (PubMed ID: 17931087)
21. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
23. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
Larkin T; Kashif R; Elsayed AH; Greer B; Mangrola K; Rafiee R; Nguyen N; Shastri V; Horn B; Lamba JK
JCO Precis Oncol; 2023 Mar; 7():e2200580. PubMed ID: 36952646
[TBL] [Abstract][Full Text] [Related]
24. Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome.
Krajinovic M; Labuda D; Sinnett D
Rev Environ Health; 2001; 16(4):263-79. PubMed ID: 12041882
[TBL] [Abstract][Full Text] [Related]
25. Genome study suggests new treatments for high-risk form of childhood leukemia.
McBride D
ONS Connect; 2012 Nov; 27(11):21. PubMed ID: 23316525
[No Abstract] [Full Text] [Related]
26. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
[TBL] [Abstract][Full Text] [Related]
27. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
[TBL] [Abstract][Full Text] [Related]
28. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic considerations of xenograft mouse models of acute leukemia.
Guihard S; Peyrouze P; Cheok MH
Pharmacogenomics; 2012 Nov; 13(15):1759-72. PubMed ID: 23171339
[TBL] [Abstract][Full Text] [Related]
30. Genetic studies in acute lymphoblastic leukemia.
Pui CH
Acta Paediatr Taiwan; 2000; 41(6):303-7. PubMed ID: 11198935
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of acute lymphoblastic leukemia.
Mehta PA; Davies SM
Curr Opin Hematol; 2004 Nov; 11(6):434-8. PubMed ID: 15548999
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
33. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui CH
Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
[TBL] [Abstract][Full Text] [Related]
34. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
35. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Mei L; Ontiveros EP; Griffiths EA; Thompson JE; Wang ES; Wetzler M
Blood Rev; 2015 Jul; 29(4):243-9. PubMed ID: 25614322
[TBL] [Abstract][Full Text] [Related]
37. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics in pediatric leukemia.
Paugh SW; Stocco G; Evans WE
Curr Opin Pediatr; 2010 Dec; 22(6):703-10. PubMed ID: 20861736
[TBL] [Abstract][Full Text] [Related]
39. Hydrocortisone does not influence glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
Warris LT; van den Heuvel-Eibrink MM; Ariës IM; Pieters R; van den Akker EL; den Boer ML
Haematologica; 2015 Apr; 100(4):e137-9. PubMed ID: 25425687
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
